Kuick Research Releases Report On Global Orphan Drug Market

Kuick Research has released a new report on the global orphan drug market. The report offers a comprehensive look at the trends in the industry and the regulatory environment worldwide. The report titled, “Global Orphan Drug Market Outlook 2018” analyzes markets by region including the U.S., Europe, and Asia. Interested parties can view statistics on the drugs in development including those in clinical trials. Insights include a market overview, the designation across markets, the regulatory framework, incentives and reimbursement policies, and a breakdown of drugs and diseases.

Kuick states that the pharmaceutical industry is slow moving across global markets. Due to the strict regulatory environment, generic drug competition, and patent expirations, growth is lagging. Authors believe that in the next five years, many best-selling drugs will lose their exclusivity and must compete with generics. The industry must adjust to this new environment and one of the best ways is to take a look at the orphan drug market. By investing in this area, companies can recoup losses from expiring brand name drugs.   

Companies can feel confident in exploring this sector because governments are increasing incentives for orphan drug development. The FDA and the EU Commission have programs for orphan drug discovery, approval, and marketing. The report authors urge pharmaceutical companies to move ahead despite the obstacles, due to the easier regulatory environment and the promise of profits. Profits are more likely, as orphan drugs have little competition and they often receive exclusive marketing approval. In effect, a company can corner the market; achieve a monopoly.    

Key Measures

For those who value numbers over insight, the report obliges. At the time of writing, 600 orphan drugs are in the clinical phase of development with 231 in Phase 2 trials. 281 drugs are approved and marketed globally. More than 30% of drugs in clinical trials are indicated for cancer. The U.S. is the leading market for orphan drugs with 350 drugs in development with sales of approved drugs at more than 40 billion.

About Kuick Research

Kuick Research is a market research company with global reach. It provides data analysis and insights on a variety of sectors and subsectors in the pharmaceutical industry. Consumers can also retrieve reports on the orphan drug market segmented by region.

 Source:

http://www.kuickresearch.com/buy-report.php?reporttitle=Global-Orphan-Drug-Market-Outlook-2018